WAICF
24.1.2023 09:26:33 CET | Business Wire | Press release
The World AI Cannes Festival will take place in Cannes on February 9, 10 and 11 2023. This is the top world event dedicated exclusively to AI, tech leaders innovating in AI and the economic, human and societal issues that will impact our lives in the short term.
The event is a chance to get up to speed on the current marketplace, learn from the best experts and to meet decision-makers and top business leaders. Many notable speakers will deliver presentations and lead strategic conferences, think-tank workshops, exhibition stands and networking sessions.
Spotlight on the major speakers for 2023
The WAICF is an opportunity for artificial intelligence professionals and experts , whether from professional backgrounds, research or public administrations, to meet and exchange views on developments in the sector.
The 100+ international speakers at the WAICF in 2023 will include:
- Yann Lecun, Vice-President and Chief AI Scientist, Meta AI
- Joann Stonier, Chief Data Officer, Mastercard
- Wolfgang Hauner, Head of Group Data Analytics, Allianz
- Saeed Contractor, Global Head of Intelligent Automation COE, Uber
- Manuela M. Veloso, Head, J. P. Morgan Chase AI Research
- Xavier Lagardere, Chief Data Officer, Vice President Data Strategy and Transformation, Lufthansa Group
- Stuart Russell, Professor of Computer Science and Michael H. Smith and Lotfi A. Zadeh Chair in Engineering, University of California, Berkeley
- Alberto Prado, Vice-President, Global Head of R&D Digital & Partnerships, Unilever
- Divya Dwivedi, Advocate, Supreme Court of India
- Aidan Gomez, Co-Founder and CEO, Cohere
- Thomas Wolf, Co-Founder and Chief Science Officer, Hugging Face
- John Kamara, Founder and CEO/founder, Adanian Labs/AI Center of Excellence (AICE)
- Michael Kearns, Amazon Scholar, University of Pennsylvania
- Michaela Schutt, SVP, Head of Global Talent Acquisition Ecosystem, Siemens
- Nozha Boujemaa, Global VP - Digital Ethics and Responsible AI, IKEA Retail
- Oren Etzioni, CEO, Allen Institute for AI
The Festival will provide an overview of AI in all its diversity through 5 key conference tracks:
- AI FOR SOCIETY: Understand the benefits of AI for society and our planet, and the challenges that must be met.
- AI TODAY AND TOMORROW: Explore what AI can do today, and picture what future innovations will offer tomorrow's society and organizations.
- AI STRATEGY: Get key insights to improve your AI strategy and take your business to the next level.
- AI TECHNOLOGY: Learn how best to use the different AI technologies, and shape your innovation mindset with top-level speakers.
- AI APPLICATIONS: Get an overview of the advances organizations can make using AI, through focuses on various industries.
Full list of conferences and speakers
Get accreditation through the media pass site
About World AI Cannes Festival
The World AI Cannes Festival brings together industry experts, professionals, and the general public to attend exhibitions, workshops, happenings, conferences, networking and meet-ups with an international dimension. The rich and varied program highlights the latest AI applications in business and in everyday life. A unique opportunity for national and international institutions, associations, businesses and start-ups across the world to meet their target audiences, highlight their expertise and demonstrate their commitment to ethical and sustainable AI.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230123005541/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom